MDxHealth (NasdaqCM:MDXH) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsJohn Fraunces - Managing Director of Investor Relations and Corporate CommunicationsKate Janson - Equity Research Associate of HealthcareMichael McGarrity - CEONelson Cox - Healthcare Equity Research AssociateRon Kalfus - Interim CFOConference Call ParticipantsBill Bonello - Senior Research AnalystOperatorGood day, welcome to the MDxHealth fourth quarter and full year 2025 earnings conference call. All particip ...

MDxHealth (NasdaqCM:MDXH) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Speaker5Good day, welcome to the MDxHealth fourth quarter and full year 2025 earnings conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by 0. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then 1 on a touchtone phone. To withdraw your question, please pre ...

Group 1: Abbott Laboratories - Abbott Laboratories has launched a significant $20 billion debt offering through an eight-tranche deal, which includes a $3.75 billion 10-year fixed-rate tranche priced at 65 basis points over Treasuries and a $3.75 billion 30-year tranche at an 80-basis-point spread [2][3][9] - The capital raise is part of Abbott's strategy to optimize its capital structure following the acquisition of Exact Sciences, with market participants noting strong investor appetite for high-grade corporate paper [3][9] Group 2: Defense Spending - The Department of Defense has submitted a reconciliation spending plan to Congress, detailing an allocation of $151.3 billion to $153.3 billion for additional defense funding, focusing on high-end military hardware [6][7][9] - Major defense contractors such as Lockheed Martin, Northrop Grumman, and General Dynamics are expected to benefit from this surge in spending, particularly in areas like missiles, drones, and naval modernization [7][9] Group 3: Global Credit Conditions - S&P Global has issued a cautious update on global credit conditions, highlighting tariff policy uncertainty as a key risk that could destabilize markets, although it does not foresee a substantial impact on immediate U.S. credit ratings [4][5][9] - The agency describes a "K-shaped" credit environment where sectors reliant on cross-border supply chains are most vulnerable to margin compression amid escalating trade tensions [5][9] Group 4: Energy Production - North Dakota's oil production reached 1.12 million barrels per day in December, with natural gas production exceeding 3.3 million MCF, indicating resilience in energy production [11] - In the coal markets, Illinois Basin coal prices rose to $54.50 per ton, while prices in other major hubs remained unchanged [12]

Core Viewpoint - Exact Sciences Corporation has received overwhelming approval from its stockholders for the acquisition by Abbott, indicating strong support for the merger [1] Company Summary - Exact Sciences Corporation is a leading provider of cancer screening and diagnostic tests [1] - The acquisition by Abbott was approved at a special meeting where more than 99% of the votes cast were in favor, representing approximately 67% of the total outstanding shares of Exact Sciences [1]

Core Insights - Exact Sciences Corporation (EXAS) reported a net loss of 21 cents per share in Q4 2025, which is higher than the loss of 6 cents in the same quarter last year, aligning with the Zacks Consensus Estimate [1] - For the full year 2025, earnings per share were 7 cents, a significant improvement from the loss of 23 cents in the previous year [1] EXAS Revenues - Q4 consolidated revenues reached $878.4 million, reflecting a 23.1% increase on a reported basis and 23% on a core revenue basis, surpassing the Zacks Consensus Estimate by 2.1% [2] - Full-year 2025 consolidated revenues totaled $3.25 billion, marking a 17.7% increase on a reported basis and 18% on a core revenue basis [2] - Following the earnings announcement, EXAS shares saw a slight increase of 0.07% [2] EXAS Q4 Segments in Detail - Screening revenues, which include laboratory service revenues from Cologuard and PreventionGenetics, amounted to $695.1 million, up 26% year over year [3] - Precision Oncology revenues, including laboratory service revenues from global Oncotype products and therapy selection products, were $183.2 million, reflecting a 14% year-over-year increase and 12% on a core basis [3] EXAS' Margins - Gross profit increased by 25% year over year to $615.8 million, with gross margin expanding by 106 basis points to 70.1% [4] - Research and development expenses rose by 96% year over year to $191.5 million, while sales and marketing expenses increased by 18% to $288.5 million [4] - General and administrative expenses grew by 14.1% year over year to $218 million [4] EXAS' Financial Update - At the end of Q4 2025, Exact Sciences had cash and cash equivalents and marketable securities totaling $964.7 million, down from $1.04 billion at the end of Q4 2024 [6] - Cumulative net cash provided by operating activities was $491.4 million, compared to $210.5 million in the previous year [6] Notable Developments - In Q4, Exact Sciences announced the first clinical study results from its Oncodetect molecular residual disease test in breast cancer, which showed favorable outcomes [10] - The company also reported pivotal clinical validation results from the ALTUS study during the quarter [10] - On November 19, 2025, Exact Sciences entered into a merger agreement with Abbott Laboratories, aiming for a close in Q2 2026, pending regulatory approvals [11]

Core Viewpoint - Investors in the Medical - Biomedical and Genetics sector should consider CSL Limited Sponsored ADR (CSLLY) and Exact Sciences (EXAS) for potential value opportunities [1] Group 1: Zacks Rank and Valuation Metrics - CSL Limited Sponsored ADR has a Zacks Rank of 2 (Buy), indicating a more favorable earnings estimate revision compared to Exact Sciences, which has a Zacks Rank of 3 (Hold) [3] - Value investors focus on various valuation metrics to identify undervalued companies, including P/E ratio, P/S ratio, earnings yield, and cash flow per share [4] Group 2: Valuation Comparisons - CSLLY has a forward P/E ratio of 15.23, significantly lower than EXAS's forward P/E of 73.88, suggesting CSLLY is more attractively priced [5] - The PEG ratio for CSLLY is 1.72, while EXAS has a PEG ratio of 2.44, indicating that CSLLY offers better value relative to its expected earnings growth [5] - CSLLY's P/B ratio is 2.4, compared to EXAS's P/B of 7.81, further supporting the notion that CSLLY is the superior value option [6]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________ FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35092 _____________________________________________________________________________ ...

Investor Contact: Derek Leckow Exact Sciences Corp. investorrelations@exactsciences.com 608-893-0009 Media Contact: Steph Spanos Exact Sciences Corp. sspanos@exactsciences.com 608-556-4380 For Immediate Release Exact Sciences Announces Record Fourth Quarter and Full Year 2025 Results Fourth quarter and 2025 highlights MADISON, Wis., Feb. 13, 2026 — Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $878 mill ...

Core Insights - Exact Sciences Corp. reported revenue of $878 million for Q4 2025 and $3.25 billion for the full year 2025, both ending December 31, 2025 [1] Group 1: Financial Performance - The company achieved a revenue of $878 million in the fourth quarter of 2025 [1] - For the full year 2025, Exact Sciences generated a total revenue of $3.25 billion [1] Group 2: Operational Highlights - In 2025, Exact Sciences screened more individuals than ever before, contributing to personalized treatment decisions [1] - The company successfully launched three new tests during the year [1]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]